Exact Mass: 473.31747720000004
Exact Mass Matches: 473.31747720000004
Found 406 metabolites which its exact mass value is equals to given mass value 473.31747720000004
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
23-Acetoxysoladulcidine
(23R)-Acetoxytomatidine is an alkaloid from roots of a Lycopersicon esculentum/Lycopersicon hirsutum hybri
Docosa-4,7,10,13,16-pentaenoyl carnitine
Docosa-4,7,10,13,16-pentaenoyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.) [HMDB] Docosa-4,7,10,13,16-pentaenoyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.).
Clupanodonyl carnitine
Clupanodonyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.) [HMDB] Clupanodonyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.).
(7Z,10Z,13Z,16Z,19Z)-Docosapentaenoylcarnitine
(7Z,10Z,13Z,16Z,19Z)-Docosapentaenoylcarnitine is an acylcarnitine. More specifically, it is an (7Z,19Z)-docosa-7,10,13,16,19-pentaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (7Z,10Z,13Z,16Z,19Z)-Docosapentaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (7Z,10Z,13Z,16Z,19Z)-Docosapentaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(9S,10E,12S,13S)-9,12,13-Trihydroxyoctadec-10-enoylcarnitine
(9S,10E,12S,13S)-9,12,13-trihydroxyoctadec-10-enoylcarnitine is an acylcarnitine. More specifically, it is an (9S,10E,12S,13S)-9,12,13-trihydroxyoctadec-10-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9S,10E,12S,13S)-9,12,13-trihydroxyoctadec-10-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (9S,10E,12S,13S)-9,12,13-trihydroxyoctadec-10-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(9S,10R,11E,13S)-9,10,13-Trihydroxyoctadec-11-enoylcarnitine
(9S,10R,11E,13S)-9,10,13-trihydroxyoctadec-11-enoylcarnitine is an acylcarnitine. More specifically, it is an (9S,10R,11E,13S)-9,10,13-trihydroxyoctadec-11-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9S,10R,11E,13S)-9,10,13-trihydroxyoctadec-11-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (9S,10R,11E,13S)-9,10,13-trihydroxyoctadec-11-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(7E,10E,13E,16E,19E)-Docosapentaenoylcarnitine
(7E,10E,13E,16E,19E)-Docosapentaenoylcarnitine is an acylcarnitine. More specifically, it is an (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (7E,10E,13E,16E,19E)-Docosapentaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (7E,10E,13E,16E,19E)-Docosapentaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
23-acetoxysoladulcidine
An organic heterohexacyclic compound that is soladulcidine carrying an acetoxy substituent at position 23
22,26-epimino-16beta,23-epoxy-23alpha-ethoxy-5alpha,25alphaH-cholest-22(N)-ene-3beta,20alpha-diol
(5S,6R)-5-(amino)-6-hydroxypoly-angioic acid|Ambruticin VS-5
C28H43NO5 (473.31410680000005)
Val Ile Lys Asp
Val Ile Asp Lys
Ala Lys Lys Lys
C21H43N7O5 (473.33255080000004)
Ala Lys Lys Gln
Ala Lys Gln Lys
Ala Gln Lys Lys
Asp Ile Lys Val
Asp Ile Val Lys
Asp Lys Ile Val
Asp Lys Leu Val
Asp Lys Val Ile
Asp Lys Val Leu
Asp Leu Lys Val
Asp Leu Val Lys
Asp Val Ile Lys
Asp Val Lys Ile
Asp Val Lys Leu
Asp Val Leu Lys
Glu Lys Val Val
Glu Val Lys Val
Glu Val Val Lys
Gly Lys Asn Arg
C18H35N9O6 (473.27101700000003)
Gly Lys Arg Asn
C18H35N9O6 (473.27101700000003)
Gly Asn Lys Arg
C18H35N9O6 (473.27101700000003)
Gly Asn Arg Lys
C18H35N9O6 (473.27101700000003)
Gly Arg Lys Asn
C18H35N9O6 (473.27101700000003)
Gly Arg Asn Lys
C18H35N9O6 (473.27101700000003)
Ile Asp Lys Val
Ile Asp Val Lys
Ile Ile Lys Thr
C22H43N5O6 (473.32131780000003)
Ile Ile Gln Thr
Ile Ile Thr Lys
C22H43N5O6 (473.32131780000003)
Ile Ile Thr Gln
Ile Lys Asp Val
Ile Lys Ile Thr
C22H43N5O6 (473.32131780000003)
Ile Lys Leu Thr
C22H43N5O6 (473.32131780000003)
Ile Lys Thr Ile
C22H43N5O6 (473.32131780000003)
Ile Lys Thr Leu
C22H43N5O6 (473.32131780000003)
Ile Lys Val Asp
Ile Leu Lys Thr
C22H43N5O6 (473.32131780000003)
Ile Leu Gln Thr
Ile Leu Thr Lys
C22H43N5O6 (473.32131780000003)
Ile Leu Thr Gln
Ile Gln Ile Thr
Ile Gln Leu Thr
Ile Gln Thr Ile
Ile Gln Thr Leu
Ile Arg Ser Val
Ile Arg Val Ser
Ile Ser Arg Val
Ile Ser Val Arg
Ile Thr Ile Lys
C22H43N5O6 (473.32131780000003)
Ile Thr Ile Gln
Ile Thr Lys Ile
C22H43N5O6 (473.32131780000003)
Ile Thr Lys Leu
C22H43N5O6 (473.32131780000003)
Ile Thr Leu Lys
C22H43N5O6 (473.32131780000003)
Ile Thr Leu Gln
Ile Thr Gln Ile
Ile Thr Gln Leu
Ile Val Asp Lys
Ile Val Lys Asp
Ile Val Arg Ser
Ile Val Ser Arg
Lys Ala Lys Lys
C21H43N7O5 (473.33255080000004)
Lys Ala Lys Gln
Lys Ala Gln Lys
Lys Asp Ile Val
Lys Asp Leu Val
Lys Asp Val Ile
Lys Asp Val Leu
Lys Glu Val Val
Lys Gly Asn Arg
C18H35N9O6 (473.27101700000003)
Lys Gly Arg Asn
C18H35N9O6 (473.27101700000003)
Lys Ile Asp Val
Lys Ile Ile Thr
C22H43N5O6 (473.32131780000003)
Lys Ile Leu Thr
C22H43N5O6 (473.32131780000003)
Lys Ile Thr Ile
C22H43N5O6 (473.32131780000003)
Lys Ile Thr Leu
C22H43N5O6 (473.32131780000003)
Lys Ile Val Asp
Lys Lys Ala Lys
C21H43N7O5 (473.33255080000004)
Lys Lys Ala Gln
Lys Lys Lys Ala
C21H43N7O5 (473.33255080000004)
Lys Lys Gln Ala
Lys Leu Asp Val
Lys Leu Ile Thr
C22H43N5O6 (473.32131780000003)
Lys Leu Leu Thr
C22H43N5O6 (473.32131780000003)
Lys Leu Thr Ile
C22H43N5O6 (473.32131780000003)
Lys Leu Thr Leu
C22H43N5O6 (473.32131780000003)
Lys Leu Val Asp
Lys Asn Gly Arg
C18H35N9O6 (473.27101700000003)
Lys Asn Arg Gly
C18H35N9O6 (473.27101700000003)
Lys Gln Ala Lys
Lys Gln Lys Ala
Lys Arg Gly Asn
C18H35N9O6 (473.27101700000003)
Lys Arg Asn Gly
C18H35N9O6 (473.27101700000003)
Lys Thr Ile Ile
C22H43N5O6 (473.32131780000003)
Lys Thr Ile Leu
C22H43N5O6 (473.32131780000003)
Lys Thr Leu Ile
C22H43N5O6 (473.32131780000003)
Lys Thr Leu Leu
C22H43N5O6 (473.32131780000003)
Lys Val Asp Ile
Lys Val Asp Leu
Lys Val Glu Val
Lys Val Ile Asp
Lys Val Leu Asp
Lys Val Val Glu
Leu Asp Lys Val
Leu Asp Val Lys
Leu Ile Lys Thr
C22H43N5O6 (473.32131780000003)
Leu Ile Gln Thr
Leu Ile Thr Lys
C22H43N5O6 (473.32131780000003)
Leu Ile Thr Gln
Leu Lys Asp Val
Leu Lys Ile Thr
C22H43N5O6 (473.32131780000003)
Leu Lys Leu Thr
C22H43N5O6 (473.32131780000003)
Leu Lys Thr Ile
C22H43N5O6 (473.32131780000003)
Leu Lys Thr Leu
C22H43N5O6 (473.32131780000003)
Leu Lys Val Asp
Leu Leu Lys Thr
C22H43N5O6 (473.32131780000003)
Leu Leu Gln Thr
Leu Leu Thr Lys
C22H43N5O6 (473.32131780000003)
Leu Leu Thr Gln
Leu Gln Ile Thr
Leu Gln Leu Thr
Leu Gln Thr Ile
Leu Gln Thr Leu
Leu Arg Ser Val
Leu Arg Val Ser
Leu Ser Arg Val
Leu Ser Val Arg
Leu Thr Ile Lys
C22H43N5O6 (473.32131780000003)
Leu Thr Ile Gln
Leu Thr Lys Ile
C22H43N5O6 (473.32131780000003)
Leu Thr Lys Leu
C22H43N5O6 (473.32131780000003)
Leu Thr Leu Lys
C22H43N5O6 (473.32131780000003)
Leu Thr Leu Gln
Leu Thr Gln Ile
Leu Thr Gln Leu
Leu Val Asp Lys
Leu Val Lys Asp
Leu Val Arg Ser
Leu Val Ser Arg
Asn Gly Lys Arg
C18H35N9O6 (473.27101700000003)
Asn Gly Arg Lys
C18H35N9O6 (473.27101700000003)
Asn Lys Gly Arg
C18H35N9O6 (473.27101700000003)
Asn Lys Arg Gly
C18H35N9O6 (473.27101700000003)
Asn Arg Gly Lys
C18H35N9O6 (473.27101700000003)
Asn Arg Lys Gly
C18H35N9O6 (473.27101700000003)
Gln Ala Lys Lys
Gln Ile Ile Thr
Gln Ile Leu Thr
Gln Ile Thr Ile
Gln Ile Thr Leu
Gln Lys Ala Lys
Gln Lys Lys Ala
Gln Leu Ile Thr
Gln Leu Leu Thr
Gln Leu Thr Ile
Gln Leu Thr Leu
Gln Thr Ile Ile
Gln Thr Ile Leu
Gln Thr Leu Ile
Gln Thr Leu Leu
Arg Gly Lys Asn
C18H35N9O6 (473.27101700000003)
Arg Gly Asn Lys
C18H35N9O6 (473.27101700000003)
Arg Ile Ser Val
Arg Ile Val Ser
Arg Lys Gly Asn
C18H35N9O6 (473.27101700000003)
Arg Lys Asn Gly
C18H35N9O6 (473.27101700000003)
Arg Leu Ser Val
Arg Leu Val Ser
Arg Asn Gly Lys
C18H35N9O6 (473.27101700000003)
Arg Asn Lys Gly
C18H35N9O6 (473.27101700000003)
Arg Ser Ile Val
Arg Ser Leu Val
Arg Ser Val Ile
Arg Ser Val Leu
Arg Thr Val Val
Arg Val Ile Ser
Arg Val Leu Ser
Arg Val Ser Ile
Arg Val Ser Leu
Arg Val Thr Val
Arg Val Val Thr
Ser Ile Arg Val
Ser Ile Val Arg
Ser Leu Arg Val
Ser Leu Val Arg
Ser Arg Ile Val
Ser Arg Leu Val
Ser Arg Val Ile
Ser Arg Val Leu
Ser Val Ile Arg
Ser Val Leu Arg
Ser Val Arg Ile
Ser Val Arg Leu
Thr Ile Ile Lys
C22H43N5O6 (473.32131780000003)
Thr Ile Ile Gln
Thr Ile Lys Ile
C22H43N5O6 (473.32131780000003)
Thr Ile Lys Leu
C22H43N5O6 (473.32131780000003)
Thr Ile Leu Lys
C22H43N5O6 (473.32131780000003)
Thr Ile Leu Gln
Thr Ile Gln Ile
Thr Ile Gln Leu
Thr Lys Ile Ile
C22H43N5O6 (473.32131780000003)
Thr Lys Ile Leu
C22H43N5O6 (473.32131780000003)
Thr Lys Leu Ile
C22H43N5O6 (473.32131780000003)
Thr Lys Leu Leu
C22H43N5O6 (473.32131780000003)
Thr Leu Ile Lys
C22H43N5O6 (473.32131780000003)
Thr Leu Ile Gln
Thr Leu Lys Ile
C22H43N5O6 (473.32131780000003)
Thr Leu Lys Leu
C22H43N5O6 (473.32131780000003)
Thr Leu Leu Lys
C22H43N5O6 (473.32131780000003)
Thr Leu Leu Gln
Thr Leu Gln Ile
Thr Leu Gln Leu
Thr Gln Ile Ile
Thr Gln Ile Leu
Thr Gln Leu Ile
Thr Gln Leu Leu
Thr Arg Val Val
Thr Val Arg Val
Thr Val Val Arg
Val Asp Ile Lys
Val Asp Lys Ile
Val Asp Lys Leu
Val Asp Leu Lys
Val Glu Lys Val
Val Glu Val Lys
Val Ile Arg Ser
Val Ile Ser Arg
Val Lys Asp Ile
Val Lys Asp Leu
Val Lys Glu Val
Val Lys Ile Asp
Val Lys Leu Asp
Val Lys Val Glu
Val Leu Asp Lys
Val Leu Lys Asp
Val Leu Arg Ser
Val Leu Ser Arg
Val Arg Ile Ser
Val Arg Leu Ser
Val Arg Ser Ile
Val Arg Ser Leu
Val Arg Thr Val
Val Arg Val Thr
Val Ser Ile Arg
Val Ser Leu Arg
Val Ser Arg Ile
Val Ser Arg Leu
Val Thr Arg Val
Val Thr Val Arg
Val Val Glu Lys
Val Val Lys Glu
Val Val Arg Thr
Val Val Thr Arg
(Z)-2-tetracos-15-enamidoethanesulfonic acid
C26H51NO4S (473.3538606000001)
CAR 22:5
N-ethyl-4-[[4-(ethylamino)-m-tolylphenyl][4-(ethylimino)-3-methylcyclohexa-2,5-dien-1-ylidene]methyl]-m-toluidine monoacetate
prednisolamate
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid
[3-(dodecyloxy)-2-hydroxypropyl]bis(2-hydroxyethyl)methylammonium methyl sulphate
ISO-Fludelone
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent
(9S,10E,12S,13S)-9,12,13-Trihydroxyoctadec-10-enoylcarnitine
(9S,10R,11E,13S)-9,10,13-Trihydroxyoctadec-11-enoylcarnitine
Ile-Arg-Trp
C23H35N7O4 (473.27503900000005)
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors
N-[(5R,6S,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C27H43N3O4 (473.32533980000005)
(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-10-[[methyl(pyridin-3-ylmethyl)amino]methyl]-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-14-one
(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-10-[[methyl(pyridin-3-ylmethyl)amino]methyl]-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-14-one
(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-10-[[methyl(pyridin-4-ylmethyl)amino]methyl]-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-14-one
N-[(4R,7R,8R)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C27H43N3O4 (473.32533980000005)
N-[(4R,7S,8S)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C27H43N3O4 (473.32533980000005)
N-[(4S,7R,8S)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C27H43N3O4 (473.32533980000005)
(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-10-[[methyl(pyridin-3-ylmethyl)amino]methyl]-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-14-one
(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-10-[[methyl(pyridin-3-ylmethyl)amino]methyl]-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-14-one
(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-10-[[methyl(pyridin-4-ylmethyl)amino]methyl]-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-14-one
N-[(4S,7R,8R)-5-(2-cyclopropyl-1-oxoethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(4R,7R,8R)-5-(2-cyclopropyl-1-oxoethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(5R,6R,9R)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C27H43N3O4 (473.32533980000005)
(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-10-[[methyl(pyridin-4-ylmethyl)amino]methyl]-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-14-one
(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-10-[[methyl(pyridin-3-ylmethyl)amino]methyl]-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-14-one
(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-10-[[methyl(pyridin-4-ylmethyl)amino]methyl]-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-14-one
N-[(4S,7S,8R)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C27H43N3O4 (473.32533980000005)
N-[(4S,7S,8S)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C27H43N3O4 (473.32533980000005)
N-[(4R,7S,8R)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C27H43N3O4 (473.32533980000005)
N-[(4S,7R,8R)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C27H43N3O4 (473.32533980000005)
N-[(4S,7S,8S)-5-(2-cyclopropyl-1-oxoethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(4R,7R,8S)-5-(2-cyclopropyl-1-oxoethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(4R,7S,8S)-5-(2-cyclopropyl-1-oxoethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(4R,7S,8R)-5-(2-cyclopropyl-1-oxoethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(4S,7R,8S)-5-(2-cyclopropyl-1-oxoethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(5S,6S,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C27H43N3O4 (473.32533980000005)
N-[(5R,6R,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C27H43N3O4 (473.32533980000005)
N-[(5S,6S,9R)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C27H43N3O4 (473.32533980000005)
N-[(5R,6S,9R)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C27H43N3O4 (473.32533980000005)
N-[(5S,6R,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C27H43N3O4 (473.32533980000005)
(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-10-[[methyl(pyridin-4-ylmethyl)amino]methyl]-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-14-one
(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-10-[[methyl(pyridin-4-ylmethyl)amino]methyl]-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-14-one
(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-10-[[methyl(pyridin-4-ylmethyl)amino]methyl]-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-14-one
(3R,19R)-19-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxyicosanoate
(3R)-20-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxyicosanoate
[3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C24H44NO6P (473.29060940000005)
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxydodec-5-enoyl]amino]dodeca-4,8-diene-1-sulfonic acid
C24H43NO6S (473.28109380000006)
(4E,8E)-2-(dodecanoylamino)-3-hydroxytrideca-4,8-diene-1-sulfonic acid
C25H47NO5S (473.31747720000004)
(E)-3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]dodec-4-ene-1-sulfonic acid
C25H47NO5S (473.31747720000004)
(4E,8E)-3-hydroxy-2-(tridecanoylamino)dodeca-4,8-diene-1-sulfonic acid
C25H47NO5S (473.31747720000004)
(4E,8E)-3-hydroxy-2-(undecanoylamino)tetradeca-4,8-diene-1-sulfonic acid
C25H47NO5S (473.31747720000004)
(E)-3-hydroxy-2-[[(Z)-tetradec-9-enoyl]amino]undec-4-ene-1-sulfonic acid
C25H47NO5S (473.31747720000004)
(4E,8E)-2-(decanoylamino)-3-hydroxypentadeca-4,8-diene-1-sulfonic acid
C25H47NO5S (473.31747720000004)
(E)-3-hydroxy-2-[[(Z)-pentadec-9-enoyl]amino]dec-4-ene-1-sulfonic acid
C25H47NO5S (473.31747720000004)
4-(3-Hexanoyloxy-2-nonanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
4-(3-Heptanoyloxy-2-octanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
4-(3-Butanoyloxy-2-undecanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
4-(3-Acetyloxy-2-tridecanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
4-(2-Decanoyloxy-3-pentanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
4-(2-Dodecanoyloxy-3-propanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
(4E,7E,10E,13E,16E,19E)-docosahexaenoylcarnitine
An O-acylcarnitine in which the acyl group is specified as (4E,7E,10E,13E,16E,19E)-docosahexaenoyl.
O-[(7Z,10Z,13Z,16Z,19Z)-docosapentaenoyl]carnitine
An O-acylcarnitine having (7Z,10Z,13Z,16Z,19Z)-docosapentaenoyl as the acyl substituent.
(4E,7E,10E,13E,16E)-docosapentaenoylcarnitine
An O-acylcarnitine in which the acyl group is specified as (4E,7E,10E,13E,16E)-docosapentaenoyl.
[1-({2-carboxy-2-[(1-hydroxyethylidene)amino]ethyl}sulfanyl)-14-methyl-3-oxohexadecan-2-yl]trimethylazanium
[C25H49N2O4S]+ (473.34128540000006)